TABLE 3.
Sensitivities, specificities, and predictive values of three HIV screening assaysa
| Test | Result type | No. of samples
|
Sensitivity (95% CI) | Specificity (95% CI) | NPV (%) | PPV (%) | |
|---|---|---|---|---|---|---|---|
| HIV-1 positive (n = 93) | HIV-1 negative (n = 290) | ||||||
| HIV DUO | Positive | 85 | 5b | 91.4 (83.8–96.2) | 98.3 (96.0–99.4) | 97.3 | 94.4 |
| Negative | 8c | 285 | |||||
| Enzymun-Test HIV Combi | Positive | 82 | 8b | 88.2 (79.8–94.0) | 97.2 (94.6–98.8) | 96.2 | 91.1 |
| Negative | 11c | 282 | |||||
| HIV-1/HIV-2 3rd Generation Plus EIA | Positive | 49d | 19b | 70.0 (57.9–80.4) | 93.4 (90.0–96.0) | 92.8 | 72.1 |
| Negative | 21c | 271 | |||||
a
Abbreviations: CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.
b
Including seroconversion samples (BBI H and N) that were reactive in the screening EIAs but p24 and Western blot negative (n = 1 for HIV DUO and HIV-1/HIV-2 3rd Generation Plus EIA and n = 2 for Enzymun-Test HIV Combi).
c
Including early seroconversion samples (n = 8) that were positive only by RT-PCR.
d
Dilutions of virus lysates were not tested with HIV-1/HIV-2 3rd Generation Plus EIA.